Broncalt®, class II medical device, in patients with chronic relapsed upper airways disease: a survey in clinical practice

Broncalt®, class II medical device, in patients with chronic relapsed upper airways disease: a survey in clinical practice

Authors

  • Gian Franco Cupido ENT Department, University of Palermo, Palermo, Italy
  • Matteo Gelardi Otolaryngology Unit, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari, Italy
  • Ignazio La Mantia ENT Department, University of Catania, Catania, Italy
  • Salvo Emanuele Aragona Center of Regenerative Medicine, Humanitas Mater Domini, Castellanza (VA), Italy
  • Claudio Vicini ENT Department, Forlì-Faenza Hospital, Italy
  • Giorgio Ciprandi Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy
  • Italian Study Group on inflammatory otorhinolaryngological disorders
DOI: https://doi.org/10.23750/abm.v90i7-S.8656

Keywords:

upper airways, exacerbated chronic disease, thermal water, hyaluronic acid, grapefruit seed extract

Abstract

Inflammation and infection are common pathogenic mechanisms involved in many otorhinolaryngological (ORL) chronic diseases. Broncalt® is a class II Medical Device containing: thermal water (Medesano, PR, Italy), hyaluronic acid, and grapefruit seed extract. It could exert a safe and effective anti-inflammatory, washing, and antimicrobial activity by virtue of these components. Therefore, the aim of the current survey, conducted in clinical practice of 84 Italian ORL centers, was to evaluate its safety and efficacy in the treatment of patients with chronic upper airways disease. The 1,817 (958 males, mean age 49 years) patients were evaluated at baseline (T0) and after one (T1) and two (T2) weeks of treatment, they were treated or not treated with Broncalt®. Signs and symptoms severity were measured by visual analogue scale. Broncalt® significantly, quickly, and safely diminished the clinical features in all sub-groups (p<0.001 for all). In conclusion, Broncalt® is a class II Medical Device able to exert a safe, quick, and effective activity in patients with chronic ORL disorders.

Downloads

Published

10-07-2019

Issue

Vol. 90 No. 7-S (2019): The nutraceuticals: a new therapeutic strategy in the management of digestive and respiratory disorders: Guest Editor: Giorgio Ciprandi

Section

ORIGINAL ARTICLES

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. 
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

How to Cite

1.
Cupido GF, Gelardi M, La Mantia I, et al. Broncalt®, class II medical device, in patients with chronic relapsed upper airways disease: a survey in clinical practice. Acta Biomed. 2019;90(7-S):36-40. doi:10.23750/abm.v90i7-S.8656
Crossref
Scopus
Google Scholar
Europe PMC